Submitted by dcc on Wed, 2017-06-21 10:58 Study Title: A Phase II trial of AZD9291 (osimertinib) with or without bevacizumab in patients with EGFR mutation positive NSCLC and brain metastasesCIRB: Adult CIRB - Early Phase EmphasisLead Group: ETCTNStatus: ActiveReview Status: Available to Open